Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study - Top-Institutions - MDSpire

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study

  • By

  • George A Yendewa

  • Temitope Olasehinde

  • Frank Mulindwa

  • Robert A Salata

  • Amir M Mohareb

  • Jeffrey M Jacobson

  • January 10, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Hepatology
    • Epidemiology

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Hepatology
    • Infectious Diseases
    • Translational Medicine

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Hepatology
    • Clinical Epidemiology

  • #4

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Public Health
    • Infectious Diseases
    • Epidemiology

  • #5

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Infectious Diseases
    • Hepatology
    • Clinical Research

Original Source(s)

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study

  • by George A Yendewa, Temitope Olasehinde, Frank Mulindwa, Robert A Salata, Amir M Mohareb, Jeffrey M Jacobson

  • January 10, 2025

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Progress and prospects for herpesvirus vaccination using gB antigens

Assessing PEPFAR’s Health Spillover Effects Beyond HIV: An Update